Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(67%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
3
50%
Ph phase_1
2
33%
Ph phase_3
1
17%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(1)
Other(1)

Detailed Status

Active, not recruiting2
Recruiting2
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

completed117%
active_not_recruiting233%
unknown117%
recruiting233%

Recent Activity

4 active trials
Showing 5 of 6
active_not_recruitingphase_3

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

NCT02542293
recruitingphase_1

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

NCT05932199
recruitingphase_2

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

NCT02029001
active_not_recruitingphase_1

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

NCT03784066
completedphase_2

Pulmonary sarcomatoid_MEDI4736+Treme

NCT03022500
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02542293Phase 3

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

Active Not Recruiting
NCT05932199Phase 1

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Recruiting
NCT02029001Phase 2

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Recruiting
NCT03784066Phase 1

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

Active Not Recruiting
NCT03022500Phase 2

Pulmonary sarcomatoid_MEDI4736+Treme

Completed
NCT03737968Phase 2

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Unknown

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6